Published in Chest on April 06, 2009
Pulmonary vascular effects of serotonin and selective serotonin reuptake inhibitors in the late-gestation ovine fetus. Am J Physiol Lung Cell Mol Physiol (2011) 0.87
Selective serotonin reuptake inhibitor use is associated with right ventricular structure and function: the MESA-right ventricle study. PLoS One (2012) 0.82
Serotonin contributes to high pulmonary vascular tone in a sheep model of persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol (2013) 0.80
Use of selective serotonin reuptake inhibitors and outcomes in pulmonary arterial hypertension. Chest (2013) 0.79
Effects of dapoxetine on cloned Kv1.5 channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol (2012) 0.76
Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. Future Cardiol (2013) 0.75
Effect of serotonin reuptake inhibitors on pulmonary hemodynamics in humans. J Clin Med Res (2011) 0.75
Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases. Front Pharmacol (2017) 0.75
Clinical classification of pulmonary hypertension. J Am Coll Cardiol (2004) 5.87
Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation (2010) 4.66
Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation (2002) 4.42
Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med (2002) 3.91
Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail (2011) 2.92
Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. JAMA Intern Med (2013) 2.36
Mitochondrial metabolism, redox signaling, and fusion: a mitochondria-ROS-HIF-1alpha-Kv1.5 O2-sensing pathway at the intersection of pulmonary hypertension and cancer. Am J Physiol Heart Circ Physiol (2007) 2.26
Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol (2003) 2.23
Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation (2010) 2.06
Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol (2008) 2.03
Perspectives on oral pulmonary hypertension therapies recently approved by the U.S. Food and Drug Administration. Ann Am Thorac Soc (2015) 2.02
Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest (2002) 1.94
Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res (2012) 1.81
Usefulness of red cell distribution width as a prognostic marker in pulmonary hypertension. Am J Cardiol (2009) 1.80
Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest (2004) 1.72
Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J Acquir Immune Defic Syndr (2002) 1.65
Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest (2006) 1.64
The REVEAL Registry risk score calculator in patients newly diagnosed with pulmonary arterial hypertension. Chest (2011) 1.58
Validation of high-resolution echocardiography and magnetic resonance imaging vs. high-fidelity catheterization in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol (2010) 1.54
Current practice for determining pulmonary capillary wedge pressure predisposes to serious errors in the classification of patients with pulmonary hypertension. Am Heart J (2012) 1.53
Hormone replacement therapy is associated with less coronary atherosclerosis in postmenopausal women. J Clin Endocrinol Metab (2003) 1.50
Lung ¹⁸F-fluorodeoxyglucose positron emission tomography for diagnosis and monitoring of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 1.42
World Health Organization Pulmonary Hypertension group 2: pulmonary hypertension due to left heart disease in the adult--a summary statement from the Pulmonary Hypertension Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant (2012) 1.42
Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hypertension. Circulation (2006) 1.37
Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol (2003) 1.37
Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med (2011) 1.31
United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant (2008) 1.26
Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension. Chest (2010) 1.22
Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension. J Heart Lung Transplant (2008) 1.18
Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant (2011) 1.16
Late gadolinium enhancement cardiovascular magnetic resonance predicts clinical worsening in patients with pulmonary hypertension. J Cardiovasc Magn Reson (2012) 1.14
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics (2008) 1.14
Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J (2010) 1.12
Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. Circulation (2008) 1.11
Takotsubo cardiomyopathy after treatment of pulmonary arterial hypertension. Pulm Circ (2012) 1.04
Association of serum creatinine with abnormal hemodynamics and mortality in pulmonary arterial hypertension. Circulation (2008) 1.04
Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry. Arthritis Care Res (Hoboken) (2014) 1.03
Three-dimensional transthoracic echocardiography to evaluate cor triatriatum in the adult. J Am Soc Echocardiogr (2006) 1.01
Elevated basic fibroblast growth factor levels in patients with pulmonary arterial hypertension. Chest (2004) 1.00
Outcomes of noncardiac, nonobstetric surgery in patients with PAH: an international prospective survey. Eur Respir J (2012) 0.96
Survivor bias and risk assessment. Eur Respir J (2012) 0.96
Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J (2002) 0.96
Current therapeutics and practical management strategies for pulmonary arterial hypertension. Am Heart J (2011) 0.96
The WHO classification of pulmonary hypertension: A case-based imaging compendium. Pulm Circ (2012) 0.95
Temporal trends and drug exposures in pulmonary hypertension: an American experience. Am Heart J (2006) 0.94
The value of approved therapies for pulmonary arterial hypertension. Am Heart J (2007) 0.94
Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol (2005) 0.94
Validation of the pulmonary hypertension connection equation for survival prediction in pulmonary arterial hypertension. Chest (2011) 0.93
Future of clinical trials for pulmonary hypertension. Circulation (2011) 0.92
QTc prolongation is associated with impaired right ventricular function and predicts mortality in pulmonary hypertension. Int J Cardiol (2012) 0.92
Value of exercise treadmill testing in the risk stratification of patients with pulmonary hypertension. Circ Heart Fail (2009) 0.91
Evolving epidemiology of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 0.90
Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre study. Heart (2011) 0.89
Diagnosis and management of pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep (2010) 0.89
Right ventricular strain in pulmonary arterial hypertension: a 2D echocardiography and cardiac magnetic resonance study. Echocardiography (2014) 0.89
How do we explain unexplained pulmonary hypertension in the elderly? Chest (2007) 0.88
Noninvasive cardiac output measurements in patients with pulmonary hypertension. Eur Respir J (2012) 0.86
Risk assessment in pulmonary hypertension associated with heart failure and preserved ejection fraction. J Heart Lung Transplant (2012) 0.85
Pulmonary hypertension. Curr Probl Cardiol (2004) 0.84
Carbon monoxide diffusing capacity and mortality in pulmonary arterial hypertension. J Heart Lung Transplant (2009) 0.83
Prostacyclin and Oral Vasodilator Therapy in Sarcoidosis-Associated Pulmonary Hypertension: A Retrospective Case Series. Chest (2015) 0.83
One-year experience with intravenous treprostinil for pulmonary arterial hypertension. J Heart Lung Transplant (2013) 0.83
Persistence of complex vascular lesions despite prolonged prostacyclin therapy of pulmonary arterial hypertension. Histopathology (2012) 0.82
Prolonged QRS duration: a new predictor of adverse outcome in idiopathic pulmonary arterial hypertension. Chest (2011) 0.81
Three-dimensional modeling of the right ventricle from two-dimensional transthoracic echocardiographic images: utility of knowledge-based reconstruction in pulmonary arterial hypertension. J Am Soc Echocardiogr (2013) 0.81
Prognostication in pulmonary arterial hypertension. Heart Fail Clin (2012) 0.81
Sample size and cost analysis for pulmonary arterial hypertension drug trials using various imaging modalities to assess right ventricular size and function end points. Circ Cardiovasc Imaging (2013) 0.80
Three-dimensional analysis of interventricular septal curvature from cardiac magnetic resonance images for the evaluation of patients with pulmonary hypertension. Int J Cardiovasc Imaging (2011) 0.80
Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition? Curr Med Res Opin (2006) 0.79
Right ventricular assist device in end-stage pulmonary arterial hypertension: insights from a computational model of the cardiovascular system. Prog Cardiovasc Dis (2012) 0.79
Relative adrenal insufficiency in severe congestive heart failure with preserved systolic function: a case report. J Cardiovasc Med (Hagerstown) (2007) 0.79
Matrix metalloproteinases in the urine of patients with pulmonary arterial hypertension. Chest (2005) 0.78
Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries. Thromb Haemost (2012) 0.77
Something subtle about death: isolated systolic pulmonary pressure. Circulation (2009) 0.77
Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease. Int J Cardiol (2013) 0.77
Pulmonary endarterectomy surgery--a technically demanding cure for WHO Group IV Pulmonary Hypertension: requirements for centres of excellence and availability in Canada. Can J Cardiol (2011) 0.77
Epidemiology of pulmonary hypertension and right ventricular failure in left heart failure. Curr Heart Fail Rep (2014) 0.77
Obliteration of the left atrial appendage for prevention of thromboembolism. J Am Coll Cardiol (2003) 0.76
New pharmacotherapies for pulmonary hypertension: where do they fit in? Curr Hypertens Rep (2014) 0.75
Pulmonary arterial hypertension with right ventricular failure: the left forgotten ventricle. Chest (2013) 0.75
Off-pump coronary bypass surgery. N Engl J Med (2003) 0.75
Reply: applying cluster analysis to data of previously published chronic heart failure trials. J Am Coll Cardiol (2015) 0.75
Polymorphisms of adrenergic receptors and the risk of heart failure. N Engl J Med (2003) 0.75
Author's reply. Pulm Circ (2013) 0.75
Out with the old, in with the new: an updated risk stratification equation for pulmonary arterial hypertension. Expert Rev Cardiovasc Ther (2010) 0.75
[New trial designs and potential therapies for pulmonary artery hypertension]. Turk Kardiyol Dern Ars (2014) 0.75
[Pulmonary arterial hypertension: epidemiology and registries]. Turk Kardiyol Dern Ars (2014) 0.75